Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments?
- PMID: 17245346
- DOI: 10.1038/ncponc0716
Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments?
Comment on
-
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.Clin Pharmacol Ther. 2006 Jul;80(1):61-74. doi: 10.1016/j.clpt.2006.03.013. Clin Pharmacol Ther. 2006. PMID: 16815318
Publication types
LinkOut - more resources
Full Text Sources